Related references
Note: Only part of the references are listed.Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions
Victor Manuel Orellana-Noia et al.
BLOOD (2022)
Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma
Thomas A. Ollila et al.
BLOOD (2021)
CNS relapse in DLBCL patients below 60 years treated with R-ACVBP, R-CHOEP, or R-CHOP: A joint analysis of LYSA and GLA/DSHNHL.
Catherine Thieblemont et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL
Magdalena Klanova et al.
BLOOD (2019)
CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP
Norbert Schmitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy
D. Villa et al.
ANNALS OF ONCOLOGY (2010)
CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
Volkmar Boehme et al.
BLOOD (2009)
Incidence and risk factors of central nervous system recurrence in aggressive lymphoma - a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
V. Boehme et al.
ANNALS OF ONCOLOGY (2007)
Share Paper
